Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR153191 dose-ranging placebo-controlled study in ankylosing spondylitis
NL-OMON34801Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sarilumab in ankylosing spondylitis (AS) (6 arms), sponsored by Sanofi. Primary endpoints: ASAS20 response at Week 12 and Best dose and dosage regimen selection. Planned start Feb 2010; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON34801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34801.